Use of Prostaglandin F 2 Alpha for Cyclophosphamide-Induced Hemorrhagic Cystitis

Abstract

Objective:

To examine the use of prostaglandin F₂ alpha in treating cyclophosphamide-induced hemorrhagic cystitis.

Data Sources:

An English language literature search using MEDLINE 1982–1993 and bibliographic reviews of related textbooks and review articles.

Study Selection:

Articles containing pertinent information regarding the therapeutic use and effects of prostaglandin F₂ alpha as a treatment for cyclophosphamide-induced hemorrhagic cystitis in humans.

Data Extraction:

Resources were evaluated and information was extracted independently.

Data Synthesis:

A review of human cases suggests that intravesical administration of prostaglandin F₂ alpha may be an effective bedside therapy for cyclophosphamide-induced hemorrhagic cystitis. Adverse reactions are limited primarily to local effects. The optimal dosage regimen of intravesical prostaglandin F₂ alpha is not clearly established.

Conclusions:

Patients with intractable vesical hemorrhage secondary to cyclophosphamide administration may benefit from bedside intravesical instillation of prostaglandin F₂ alpha. Information in the literature regarding prostaglandin bladder irrigation is scarce, and confined to case reports. Clinical studies are needed to endorse and/or refute the efficacy of intravesical instillation of prostaglandin F₂ alpha as a treatment modality for hemorrhagic cystitis.